Nephrotic Syndrome clinical trials

Explore recruiting nephrotic syndrome clinical trials.

Recruiting nephrotic syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nephrotic Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

BOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Maintenance Therapy for Relapsing Nephrotic Syndrome Due to Podocytopathies in Adults.

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

The MEMORINEPH study: Memory B cell level-based tailored treatment with Rixathon in children with complicated forms of steroid-sensitive Nephrotic syndrome

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm, open, prospective, intervention trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome

Poland, Germany, Belgium, Italy, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrome and in patients intolerant to rituximab (the ORION study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Nephrotic Syndrome trials by city

Nephrotic Syndrome in Toronto Nephrotic Syndrome in Vancouver Nephrotic Syndrome in Montreal Nephrotic Syndrome in Calgary Nephrotic Syndrome in Edmonton Nephrotic Syndrome in Ottawa Nephrotic Syndrome in Winnipeg Nephrotic Syndrome in Quebec City Nephrotic Syndrome in Hamilton Nephrotic Syndrome in Kitchener Nephrotic Syndrome in London Nephrotic Syndrome in Halifax Nephrotic Syndrome in New York Nephrotic Syndrome in Los Angeles Nephrotic Syndrome in Chicago Nephrotic Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease